Traxion Sab De Cv Ord Shs GRPOF

RE:DIN# vs blanket coverage discussion...

[Fogcity87]

Excellent post leaf as always. I am too long on Tbp. As I have said before iv been here since grow pros. Yesterday I purchased additional shares which I will admit I reduced again today because of this topic specially. As of yesterday tbp because of its clinical trials and likely Din # were in a position to have monopoly over medical cannabis and that first mover advantage. All of the reasons provided by the members of this group including doctors wanting to prescribe based on evidence based practice have merit. In addition having that din number so patients could have coverage for their prescriptions through their insurer would not only encourage those who prefer their rxprinceps, but would also attract those who don't want to pay for their medication out of pocket to convert to tetras product. Having both a physician who is comfortable prescribing and a patient who is requesting would have those products offered by tetra capture the majority of market share in my opinion. Having insurers like sunlife provide blanket coverage under medical services and equipment eliminates at least a portion of the benefit of a din number as the value of the company comes from their ability to have there patients utilize insurance coverage whereby the insurer pays tetra. As leaf states we are now betting on doctors prescribing din number medication vs blanket coverage bud. At this point having that coverage only available to those with rhumotoid artiritis or at the end stage of their disease with cancer or Hiv isnt too big of a concern but does suggest that by offering this coverage in March, Sunlife specifically isn't overly concerned about there being no medical bud that has completed clinical trials. If this coverage expands to say pain management in the general population, including those who previously utilized opiods, ect than it becomes a much larger concern as this encompasses a much larger portion of the population. Especially as sterotypes that revolve around MJ usage decrease and acceptance increases amongst the public and physicians that thc/cbd is a viable treatment option. It's possible that tetras research and clinical trials don't benefit tetra exclusively but rather all of those companies that offer "medical" mj. From what annouced it seems as though this benefit would have to be purchased and isnt like it would be available to all users at this time say through a provincial benefits plan. There is zero doubt in my mind that more physicians will lean toward that evidenced based prescription rather than the blanket coverage, as medicine is a evidenced based profession. The fact that there will be some physicians who will continue to choose the blanket coverage for their patients, and in addition their will be those patient's who will no doubt request their favorite bud and still receive coverage is a negative. There is no way to swing that point as a positive. This was not even something i had considered as of yesterday to be honest. It is possible i am the only who havent considered this prior . Tetra has single handly provided me with financial stability and I still believe in the company, although I admit I have reduced my expectations for future SP. I too will continue a position here and move those extra funds to aph as it is my opinion that they're the ones to benefit if continued blanket coverage will become the norm while also indirectly supporting my investment in tetra. I wish everyone the best of luck, my original investment will be there to see how this progresses.